Attached files
file | filename |
---|---|
EX-21.1 - EX-21.1 - AKCEA THERAPEUTICS, INC. | a2232137zex-21_1.htm |
EX-10.11 - EX-10.11 - AKCEA THERAPEUTICS, INC. | a2232137zex-10_11.htm |
EX-10.3 - EX-10.3 - AKCEA THERAPEUTICS, INC. | a2232137zex-10_3.htm |
EX-10.2 - EX-10.2 - AKCEA THERAPEUTICS, INC. | a2232137zex-10_2.htm |
EX-5.1 - EX-5.1 - AKCEA THERAPEUTICS, INC. | a2232137zex-5_1.htm |
EX-4.1 - EX-4.1 - AKCEA THERAPEUTICS, INC. | a2232137zex-4_1.htm |
EX-3.2 - EX-3.2 - AKCEA THERAPEUTICS, INC. | a2232137zex-3_2.htm |
EX-3.1 - EX-3.1 - AKCEA THERAPEUTICS, INC. | a2232137zex-3_1.htm |
S-1/A - S-1/A - AKCEA THERAPEUTICS, INC. | a2232137zs-1a.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated March 27, 2017 (except for the second paragraph in Note 9, as to which the date is June 20, 2017), in Amendment No. 3 to the Registration Statement (Form S-1 No. 333-216949) and related Prospectus of Akcea Therapeutics, Inc. for the registration of shares of its common stock.
/s/ ERNST & YOUNG LLP | ||
San Diego, California June 20, 2017 |
Consent of Independent Registered Public Accounting Firm